Potential novel therapeutic strategies for neuropathic pain

被引:7
|
作者
Du, Zelu [1 ]
Zhang, Jian [1 ]
Han, Xu [1 ]
Yu, Weifeng [1 ]
Gu, Xiyao [1 ]
机构
[1] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Anesthesiol, Shanghai, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
neuropathic pain; clinical trial; drug targets; physical means; therapeutic strategies; LOW-BACK-PAIN; SPINAL-CORD; POSTHERPETIC NEURALGIA; STRESS REDUCTION; DOUBLE-BLIND; USUAL CARE; NERVE; PATCH; COMBINATION; POPULATION;
D O I
10.3389/fnmol.2023.1138798
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Purpose To explore the potential therapeutic strategies of different types of neuropathic pain (NP) and to summarize the cutting-edge novel approaches for NP treatment based on the clinical trials registered on .Methods The relevant clinical trials were searched using Dec 08, 2022. NP is defined as a painful condition caused by neurological lesions or diseases. All data were obtained and reviewed by the investigators to confirm whether they were related to the current topic.Results A total of 914 trials were included in this study. They were divided into painful diabetic neuropathy (PDN), postherpetic neuralgia (PHN), sciatica (SC), peripheral nerve injury-related NP (PNI), trigeminal neuralgia (TN), chemotherapy-induced NP (CINP), general peripheral NP (GPNP) and spinal cord injury NP (SCI-NP). Potential novel therapeutic strategies, such as novel drug targets and physical means, were discussed for each type of NP.Conclusion NP treatment is mainly dominated by drug therapy, and physical means have become increasingly popular. It is worth noting that novel drug targets, new implications of conventional medicine, and novel physical means can serve as promising strategies for the treatment of NP. However, more attention needs to be paid to the challenges of translating research findings into clinical practice.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Characterization of CM-398, a Novel Selective Sigma-2 Receptor Ligand, as a Potential Therapeutic for Neuropathic Pain
    Wilson, Lisa L.
    Alleyne, Amy R.
    Eans, Shainnel O.
    Cirino, Thomas J.
    Stacy, Heather M.
    Mottinelli, Marco
    Intagliata, Sebastiano
    McCurdy, Christopher R.
    McLaughlin, Jay P.
    MOLECULES, 2022, 27 (11):
  • [42] Problems and strategies for the treatment of neuropathic pain
    WiesenfeldHallin, Z
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1997, 356 (04) : 110 - 110
  • [43] Exploring Novel Therapeutic Targets in the Common Pathogenic Factors in Migraine and Neuropathic Pain
    Tajti, Janos
    Szok, Delia
    Csati, Anett
    Szabo, Agnes
    Tanaka, Masaru
    Vecsei, Laszlo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (04)
  • [44] Chronic Neuropathic Pain: PTPRD Phosphatase Inhibitors Provide Novel Therapeutic Approaches
    Uhl, George R.
    ANNALS OF NEUROLOGY, 2023, 94 : S152 - S153
  • [45] Pharmacological strategies in relieving neuropathic pain
    McCleane, G
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (06) : 1299 - 1312
  • [46] Identification of novel therapeutic targets for neuropathic pain based on gene expression patterns
    Zhu, Di
    Liu, Kang
    Wan, Cheng-Liang
    Lu, Jangnin
    Zhao, Hong-Xia
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (11) : 19494 - 19501
  • [47] Emerging Strategies for the Treatment of Neuropathic Pain
    Cheville, Andrea
    Basford, Jeffrey
    PHYSICAL THERAPY REVIEWS, 2007, 12 (01) : 74 - 74
  • [48] Exploration of novel therapeutic targets for neuropathic pain based on the regulation of immune cells
    Kobayashi, Yuka
    Kiguchi, Norikazu
    Saika, Fumihiro
    Kishioka, Shiroh
    JAPANESE JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2015, 35 (03): : 65 - 72
  • [49] Neuropathic Pain and Lung Delivery of Nanoparticulate Drugs: An Emerging Novel Therapeutic Strategy
    Islam, Nazrul
    Abbas, Muzaffar
    Rahman, Shafiqur
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2017, 16 (03) : 303 - 310
  • [50] Novel therapeutic approach to neuropathic pain: "Hot" and "Cool" TRP channel family
    Kamei, Tatsuya
    Miyauchi, Masanori
    Oyamada, Yoshihiro
    Shimizu, Isao
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2012, 118 : 39P - 39P